Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives

doi:10.5306/wjco.v12.i10.868

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7253)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

468

WORD

233

HTML

4020

Figures (1-2)

241

Tables (1-2)

297

Sum=5259

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

298

Download

662

Sum=960

Publishing Process of This Article

Item

Count

Browse

394

Download

640

Sum=1034

Oct 24, 2021 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Oct 24, 2021; 12(10): 868-881
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.868

Full Size Figure Download Figure

Figure 1 Human epidermal growth factor receptor 2 testing for serous carcinoma used in the Phase 2 clinical trial[37,46]. IHC: Immunohistochemistry; FISH: Fluorescent in situ hybridization.

Citation: Saito A, Yoshida H, Nishikawa T, Yonemori K. Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. World J Clin Oncol 2021; 12(10): 868-881
URL: https://www.wjgnet.com/2218-4333/full/v12/i10/868.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i10.868